PubMedCrossRef 24. Webber K, Mok K, Bennett B, Lloyd AR, Friedlander M, Juraskova I, Goldstein D: If I am in the mood, I enjoy it: an
exploration of cancer-related fatigue and sexual functioning in women with breast cancer. Oncologist 2011, 16:1333–1344.PubMedCrossRef 25. Taylor S, Harley C, Ziegler L, Brown J, Velikova G: Interventions for sexual problems following treatment for breast cancer: a systematic review. Breast Cancer Res Treat 2011, 130:711–724.PubMedCrossRef 26. Krychman ML, Katz A: Breast cancer and sexuality: multi-modal treatment options. J Sex Med 2012, 9:5–13. jsm_2566 5..13PubMedCrossRef 27. Moghassemi S, Ziaei S, Haidari Z: Female sexual dysfunction in Iranian postmenopausal women: prevalence and correlation SBE-��-CD with hormonal profile. J
Sex Med 2011, 8:3154–3159.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions NM together Selleck Idasanutlin with FZB contributed to the process of data collection, and data entry. IH contributed to design and patient recruitment. AM contributed to the analysis and wrote the paper. KZ contributed to design and analysis. All authors read and approved the final manuscript.”
“Background Globally, lung cancer was the most commonly diagnosed cancer and the leading cause of cancer death in males, comprising 13% (1.6 million) of the total cases of cancer and 18% (1.4 million) of total cancer S63845 solubility dmso deaths in 2008 [1]. The main clinical types Interleukin-2 receptor of lung cancer are small cell lung cancer(SCLC) and non-small cell lung cancer (NSCLC). NSCLC represents almost 80% of lung cancer, which is the leading cause of cancer-related
death in the world. The most common types of NSCLC are squamous cell lung carcinoma, adenocarcinoma, and large cell lung cancer. Surgical resection with adjuvant chemotherapy is the preferred approach for early stage NSCLC, while patients with advanced NSCLC are usually treated with chemotherapy or radiation therapy. Despite advances in treatment, the prognosis is generally poor. Following complete surgical resection of stage IA disease, 5-year survival of patients is 67%, but the 5-year survival rate of individuals with stage IV NSCLC is below 1% [2]. One reason for such a low survival rate is that patients do not receive treatment early enough in disease progression for it to be effective, which is associated with the high metastasis character of NSCLC. Progression from low- to high -stage lung cancer is related to various molecular alterations. However, the cytogenetic and molecular data on various forms of NSCLC are still being investigated for better understanding the disease. The molecular mechanism underlying the progression of NSCLC requires further research, with a view to basing therapy on molecular signatures within tumors. There is significant clinical value in early detection and provision of effective interventions to treat NSCLC.